Cargando…

Healthcare resource utilization in patients treated with empagliflozin in East Asia

AIMS/INTRODUCTION: We investigated the utilization of healthcare resources in patients with type 2 diabetes treated with empagliflozin, a sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor, versus dipeptidyl peptidase‐4 (DPP‐4) inhibitors in clinical practice in Japan, South Korea, and Taiwan. MATERI...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sheu, Wayne H‐H, Seino, Yutaka, Tan, Elise Chia‐Hui, Yabe, Daisuke, Ha, Kyoung Hwa, Nangaku, Masaomi, Chung, Wook‐Jin, Node, Koichi, Yasui, Atsutaka, Lei, Wei‐Yu, Lee, Sunwoo, Ustyugova, Anastasia, Klement, Riho, Deruaz‐Luyet, Anouk, Kyaw, Moe H, Kim, Dae Jung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9077718/ https://www.ncbi.nlm.nih.gov/pubmed/34859609 http://dx.doi.org/10.1111/jdi.13728

Ejemplares similares

Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study
por: Seino, Yutaka, et al.
Publicado: (2020)

Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study
por: Kim, Dae Jung, et al.
Publicado: (2023)

Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I–III clinical trials
por: Yabe, Daisuke, et al.
Publicado: (2018)

Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes
por: Yabe, Daisuke, et al.
Publicado: (2021)

The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care
por: Patorno, Elisabetta, et al.
Publicado: (2019)

Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
por: Vistisen, Dorte, et al.
Publicado: (2023)

Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics
por: Htoo, Phyo T., et al.
Publicado: (2022)

The clinical burden of newly diagnosed Heart failure among patients with Reduced, mildly Reduced, and preserved ejection fraction
por: Nichols, Gregory A., et al.
Publicado: (2023)

Epidemiology of Asymptomatic Pre-heart Failure: a Systematic Review
por: Bergamasco, Aurore, et al.
Publicado: (2022)

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China
por: Ramos, Mafalda, et al.
Publicado: (2021)

Potential paraneoplastic syndromes and selected autoimmune conditions in patients with non-small cell lung cancer and small cell lung cancer: A population-based cohort study
por: Miret, Montserrat, et al.
Publicado: (2017)

Prevalence of multimorbidity in general practice: a cross-sectional study within the Swiss Sentinel Surveillance System (Sentinella)
por: Excoffier, Sophie, et al.
Publicado: (2018)

Incidence of lower extremity amputations among patients with type 1 and type 2 diabetes in the United States from 2010 to 2014
por: Déruaz‐Luyet, Anouk, et al.
Publicado: (2020)

Empagliflozin Induces Transient Diuresis Without Changing Long-Term Overall Fluid Balance in Japanese Patients With Type 2 Diabetes
por: Yasui, Atsutaka, et al.
Publicado: (2018)

β Cell Dysfunction Versus Insulin Resistance in the Pathogenesis of Type 2 Diabetes in East Asians
por: Yabe, Daisuke, et al.
Publicado: (2015)

Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK
por: Ramos, Mafalda, et al.
Publicado: (2020)

Incretin‐based drugs for type 2 diabetes: Focus on East Asian perspectives
por: Seino, Yutaka, et al.
Publicado: (2016)

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME(®) trial
por: Kadowaki, Takashi, et al.
Publicado: (2019)

The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non‐Asian populations of the EMPA‐REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease
por: Kaku, Kohei, et al.
Publicado: (2022)

Safety and Efficacy of Empagliflozin as Add-On Therapy to GLP-1 Receptor Agonist (Liraglutide) in Japanese Patients with Type 2 Diabetes Mellitus: A Randomised, Double-Blind, Parallel-Group Phase 4 Study
por: Terauchi, Yasuo, et al.
Publicado: (2019)

Comparing the self-perceived quality of life of multimorbid patients and the general population using the EQ-5D-3L
por: N’Goran, Alexandra A., et al.
Publicado: (2017)

Correction to: Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes
por: Nichols, Gregory A., et al.
Publicado: (2020)

Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes
por: Nichols, Gregory A., et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease
por: Ramos, Mafalda, et al.
Publicado: (2019)

Healthcare Resource Utilization and Costs for Empagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists in Routine Clinical Care in Denmark
por: Thomsen, Reimar W., et al.
Publicado: (2022)

Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4‐week, double‐blind, randomized, placebo‐controlled phase 2 trial
por: Shimada, Akira, et al.
Publicado: (2018)

Dietary recommendations for type 2 diabetes patients: Lessons from recent clinical and basic research in Asia
por: Seino, Yusuke, et al.
Publicado: (2019)

Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials
por: Tuttle, Katherine R., et al.
Publicado: (2022)

Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons
por: Balijepalli, Chakrapani, et al.
Publicado: (2018)

Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study
por: Thomsen, Reimar W., et al.
Publicado: (2021)

Incretin concept revised: The origin of the insulinotropic function of glucagon‐like peptide‐1 – the gut, the islets or both?
por: Yabe, Daisuke, et al.
Publicado: (2017)

Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease
por: Reifsnider, Odette S, et al.
Publicado: (2021)

Empagliflozin in Patients with Chronic Kidney Disease
por: Herrington, William G., et al.
Publicado: (2023)

Rationale and design of the EMPERIAL‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure
por: Abraham, William T., et al.
Publicado: (2019)

Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference
por: Yabe, Daisuke, et al.
Publicado: (2011)

Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
por: Yabe, Daisuke, et al.
Publicado: (2014)

Dipeptidyl peptidase‐4 inhibitors and prevention of bone fractures: Effects beyond glyemic control
por: Yabe, Daisuke, et al.
Publicado: (2012)

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas
por: Seino, Yutaka, et al.
Publicado: (2013)

Cardiovascular safety trials of incretin‐based drugs: What do they mean?
por: Yabe, Daisuke, et al.
Publicado: (2016)

Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure
por: Reifsnider, Odette S., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u1p4dm030m7jv2a1uq21hiv5fm